Sugi Predict

Sugi Predict / Compounds / SCHEMBL12437748

SCHEMBL12437748

SCHEMBL12437748

CCN(CCCNC(=O)c1cnc(OC2CCN(Cc3ccc4c(c3)c3ccccc3n4CC)CC2)c(Cl)c1)Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 5/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ LMNA P02545 3/20 0.45
▸ GLA P06280 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ USP7 Q93009 2/20 0.42
▸ FAAH O00519 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ CXCR3 P49682 5/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437761 0.88 TP53 (0.45) TP53SMN1; SMN2LMNAHTTFAAH
SCHEMBL12437770 0.83 UTS2R (0.46) TP53SMN1; SMN2LMNAGLAHTT
SCHEMBL12437767 0.83 USP7 (0.44) TP53SMN1; SMN2LMNAUSP7MAPT
SCHEMBL12437755 0.83 UTS2R (0.47) TP53SMN1; SMN2LMNAGLAHTT
SCHEMBL12437801 0.82 TMEM97 (0.50) TP53SMN1; SMN2USP7FAAHMAPT
SCHEMBL12437773 0.81 UTS2R (0.45) TP53SMN1; SMN2LMNAGLAHTT
SCHEMBL12437869 0.81 MCHR2 (0.43) TP53SMN1; SMN2LMNAHTTFAAH
SCHEMBL12513652 0.81 SLC5A7 (0.51) TP53SMN1; SMN2LMNAFAAHMAPT
SCHEMBL12437803 0.79 UTS2R (0.46) TP53SMN1; SMN2LMNAFAAHMAPT
SCHEMBL12437727 0.79 UTS2R (0.45) TP53SMN1; SMN2LMNAHTTFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 — — US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 — — US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 — — US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 — — US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 — — US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 — — US disclosed
WO-2008133975-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2008-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF TP53, BCOR, HPGDS TP53 1/4885SMN1; SMN2 4775/4885LMNA 3158/4885
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD TP53 7/4885SMN1; SMN2 4539/4885LMNA 2809/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD TP53 7/4885SMN1; SMN2 4539/4885LMNA 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.